Almirall Bilan de santé

Santé financière contrôle des critères 6/6

Almirall possède un total de capitaux propres de €1.5B et une dette totale de €346.7M, ce qui porte son ratio d'endettement à 23.6%. Son actif total et son passif total sont €2.3B et de €839.2M. L'EBIT de Almirall est €37.0M ce qui fait que son ratio de couverture des intérêts 4.5. Elle dispose de liquidités et de placements à court terme de €343.1M.

Informations clés

23.6%

Ratio d'endettement

€346.70m

Dette

Ratio de couverture des intérêts	4.5x
Argent liquide	€343.10m
Fonds propres	€1.47b
Total du passif	€839.20m
Total des actifs	€2.31b

Mises à jour récentes de la santé financière

Recent updates

Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nov 14

Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet

Nov 06

Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)

Sep 07

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Jul 12

Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

Apr 24

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Mar 20

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Dec 15

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

Oct 03

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Aug 24

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Jul 05

Is Almirall (BME:ALM) A Risky Investment?

May 16

Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

Mar 29

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Jan 04

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Dec 01

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Jul 14

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Mar 23

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Feb 24

Is Almirall (BME:ALM) Using Too Much Debt?

Nov 01

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Aug 02

Is Almirall (BME:ALM) Using Too Much Debt?

Jul 06

Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

Mar 23

How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock?

Mar 05

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ALM ( €704.4M ) dépassent ses passifs à court terme ( €270.3M ).

Passif à long terme: Les actifs à court terme de ALM ( €704.4M ) dépassent ses passifs à long terme ( €568.9M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de ALM ( 0.2% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de ALM a été réduit de 42.1% à 23.6% au cours des 5 dernières années.

Couverture de la dette: La dette de ALM est bien couverte par le flux de trésorerie opérationnel ( 43.1% ).

Couverture des intérêts: Les paiements d'intérêts de ALM sur sa dette sont bien couverts par l'EBIT ( 4.5 x couverture).

Almirall Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Is Almirall (BME:ALM) A Risky Investment?

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Recent updates

Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Third quarter 2024 earnings released

Almirall, S.A. Reiterates Earnings Guidance for Full Year 2024

Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet

Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)

Second quarter 2024 earnings released

Almirall, S.A. Reiterates Financial Guidance for Full Year 2024

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Insufficient new directors

Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year

Dividend of €0.15 announced

Almirall, S.A. Provides Earnings Guidance for Full Year 2024

Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

Almirall, S.A., Annual General Meeting, May 10, 2024

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS misses analyst expectations

Almirall, S.A. Provides Earnings Guidance for the Year 2024

Consensus EPS estimates increase by 15%

Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Consensus EPS estimates increase by 29%

Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis

Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022)

Almirall, S.A. to Report Fiscal Year 2023 Results on Feb 19, 2024

Almirall's Ilumetri (Tildrakizumab) Significantly Improves Wellbeing for Patients and Their Relatives in Moderate-To-Severe Plaque Psoriasis

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

Now 21% undervalued

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

New minor risk - Shareholder dilution

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Almirall Launches Nina, the First Series to Highlight the Major Impact of Psoriasis on Patient’s Wellbeing

Almirall, S.A. has completed a Follow-on Equity Offering in the amount of €199.999993 million.

New minor risk - Dividend sustainability

Is Almirall (BME:ALM) A Risky Investment?

First quarter 2023 earnings released

Consensus EPS estimates fall by 26%

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

Full year 2022 earnings released: EPS: €0.02 (vs €0.23 loss in FY 2021)

Almirall, S.A., Annual General Meeting, May 05, 2023

Now 20% undervalued after recent price drop

Price target decreased by 7.2% to €11.93

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Now 20% undervalued

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Almirall, S.A. to Report Nine Months, 2023 Results on Nov 16, 2023

Almirall, S.A. Maintains Earnings Guidance for the Full Year of 2022

Almirall, S.A. Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Lebrikizumab in Atopic Dermatitis

Almirall, S.A. Announces the 31st EADV Congress the Results from TRIBUTE, an Interventional Phase IV Clinical Study

Almirall, S.A. Announces New Detailed Results from Phase 3 Monotherapy Studies in Atopic Dermatitis

Second quarter 2022 earnings: EPS misses analyst expectations

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Almirall, S.A.(BME:ALM) dropped from Madrid Ibex 35 Index

Happify Health and Almirall, S.A. Go Live with Digital Solution to Support Psoriasis Patients

Almirall, S.A. Announces Topline Results from One-Year Analyses of the Efficacy and Safety of Lebrikizumab

Almirall, S.A. Announces Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

Now 21% undervalued

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Now 22% undervalued

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Full year 2021 earnings: EPS and revenues miss analyst expectations

Almirall, S.A. Announces Executive Changes

Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp

Almirall Announces Results for Atopic Dermatitis in Third Phase 3 Study

Price target decreased to €14.66

Is Almirall (BME:ALM) Using Too Much Debt?

Almirall, S.A. Launches Klisyri (Tirbanibulin) for the Treatment of Actinic Keratosis in Europe